Acceleron To Be Next M&A Target With Rumored $11bn Deal
BMS Seen As Most Likely Suitor
Executive Summary
The Cambridge, MA-based biotech has one blockbuster-tipped drug already on the market, with another in pivotal studies.
You may also be interested in...
Acceleron Investors Want Merck To Pay More, Ask Company To Wait For Better Offer
Avoro Capital, Holocene Advisors and Darwin Global say that Acceleron should sell later for a higher price based on forthcoming data or Merck should raise its bid above $180 per share.
Merck’s $11.5bn Acceleron Buy Partially Fills Future Keytruda Revenue Gap
The company announced the biggest biopharma M&A deal of the year so far, but Merck will need more large deals to manage declining sales when its top-selling product faces biosimilars in 2028.
Merck Closes In On Acceleron But BMS And Anti-Trust Regulators Could Be Obstacles
Biopharma M&A has had a quiet year so far but could heat up if rivals start vying for the biotech company.